ENDRA Life Sciences Granted Extension To Regain Compliance With Nasdaq Continued Listing Requirements
Portfolio Pulse from Benzinga Newsdesk
ENDRA Life Sciences Inc. has been granted an extension by Nasdaq to regain compliance with the $1.00 bid price requirement for continued listing. The company has until November 20, 2024, to achieve a closing bid price of at least $1.00 per share for 10 consecutive trading sessions.
August 28, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ENDRA Life Sciences has been given until November 20, 2024, to comply with Nasdaq's $1.00 bid price requirement. The company is exploring options to meet this requirement.
The extension provides ENDRA Life Sciences more time to meet Nasdaq's listing requirements, which is crucial for maintaining its listing status. The company's stock price may experience volatility as it works to meet the $1.00 bid price requirement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100